Doxorubicin generates a proapoptotic phenotype by phosphorylation of elongation factor 2.
about
A pharmacoproteomic approach implicates eukaryotic elongation factor 2 kinase in ER stress-induced cell deathInterspecies scaling of a camptothecin analogue: human predictions for intravenous topotecan using animal data.Oxidative stress sensitizes bladder cancer cells to TRAIL mediated apoptosis by down-regulating anti-apoptotic proteinsThe translation elongation factor eEF2 is a novel tumor‑associated antigen overexpressed in various types of cancers.Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels.Dihydroartemisinin enhances Apo2L/TRAIL-mediated apoptosis in pancreatic cancer cells via ROS-mediated up-regulation of death receptor 5ZAK is required for doxorubicin, a novel ribotoxic stressor, to induce SAPK activation and apoptosis in HaCaT cells.Parallel screening of FDA-approved antineoplastic drugs for identifying sensitizers of TRAIL-induced apoptosis in cancer cells.Germline quality control: eEF2K stands guard to eliminate defective oocytesTransformation, translation and TRAIL: an unexpected intersection.The role of protein synthesis in cell cycling and cancerThe alpha-kinase family: an exceptional branch on the protein kinase tree.Modulation of chemotherapy-induced cytotoxicity in SH-SY5Y neuroblastoma cells by caffeine and chlorogenic acid.Suppression of vascular endothelial growth factor via inactivation of eukaryotic elongation factor 2 by alkaloids in Coptidis rhizome in hepatocellular carcinoma.Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling.
P2860
Q28576403-5459B508-5747-40DB-A7FE-92725E4C8D35Q33378927-55E5E7A6-FB2F-4D1D-B50D-6A55EF3C5FF8Q33485621-455C3AF0-57F1-408A-9C83-526937045E6CQ33636990-2F418245-DD8A-4879-9C50-F6B4EA3D0656Q34101055-B9C8F65C-CAA3-438B-9BC5-64ABBD6D8F8CQ34292461-E7722665-9901-4E48-8431-05514CFD0E93Q34581761-C174E366-83E3-4181-BF8D-BCEFF8837376Q35570425-9C45E745-8136-4CCE-8444-FD3930D508EBQ36461799-234277DE-41DA-48C3-9E36-6964DF76AD9BQ36571532-6CDA5900-7195-403E-9EAD-FFD7FC09513AQ37442358-53B45B9E-E299-4EE4-A691-F974D2016551Q37655393-710A9C5D-2849-49BE-83E6-D0F02A1101C7Q38712990-F85FAC38-5598-41D9-86B9-40259AF9E28CQ39040936-2B247417-8AE1-4CCF-9F7A-9DE5393E6A39Q39179377-BB584AFE-9E55-4CDA-8F4C-55210C4B0792
P2860
Doxorubicin generates a proapoptotic phenotype by phosphorylation of elongation factor 2.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Doxorubicin generates a proapoptotic phenotype by phosphorylation of elongation factor 2.
@ast
Doxorubicin generates a proapoptotic phenotype by phosphorylation of elongation factor 2.
@en
type
label
Doxorubicin generates a proapoptotic phenotype by phosphorylation of elongation factor 2.
@ast
Doxorubicin generates a proapoptotic phenotype by phosphorylation of elongation factor 2.
@en
prefLabel
Doxorubicin generates a proapoptotic phenotype by phosphorylation of elongation factor 2.
@ast
Doxorubicin generates a proapoptotic phenotype by phosphorylation of elongation factor 2.
@en
P2093
P2860
P1476
Doxorubicin generates a proapoptotic phenotype by phosphorylation of elongation factor 2.
@en
P2093
Christina Voelkel-Johnson
Laura M Kasman
Laura Spruill
Margaret M Kelly
Paul J McDermott
Shai J White
P2860
P304
P356
10.1016/J.FREERADBIOMED.2007.06.015
P577
2007-07-03T00:00:00Z